Replies to post #13908 on Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

On June 17, 2015, Momenta Pharmaceuticals, Inc. ("Momenta") and Sandoz AG and Sandoz Inc. (together "Sandoz") entered into a letter agreement (the "Amendment") amending the Collaboration and License Agreement, dated November 1, 2003, by and between Momenta and Sandoz (the "Agreement") relating to, among other things, the development and commercialization of Enoxaparin Sodium Injection, a generic version of Lovenox?. As amended, Sandoz's obligation under the Agreement to pay Momenta a royalty on net sales of Enoxaparin Sodium Injection is replaced, effective as of April 1, 2015, with an obligation to pay 50% of contractually-defined profits on sales of Enoxaparin Sodium Injection.